SEARCH RESULTS FOR:

Sanjay Ahuja

GENERAL MANAGER, EPIROC
Atlas Copco rebranded its mining products under the new name Epiroc at the end of last year which will become a separate company.

Gerson Moacir Secomandi

COMMERCIAL DIRECTOR, OXITENO MEXICO
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Oxiteno is expanding its presence in North America with new facilities in both Mexico and USA.

Dr. Wu Xiaobing

COUNTRY MANAGER, PFIZER CHINA & REGIONAL PRESIDENT, PFIZER ESSENTIAL HEALTH GREATER CHINA
Pfizer speaks to GBR about its operations in China.

Xavier Benoit & M. Nikhil Mallavarapu

CENTUM ADENEO
Centum Adeneo is part of the Centum group, and has a strong expertise in all forms of electronics.

Ted O'Connor & Laurence Stefan

CEO & PRESIDENT AND COO, PLATEAU ENERGY METALS
Peru Mining 2018 Pre-Release
Plateau Energy Metals speaks to GBR about its recent Falchani discovery in Peru.

Karim Chibane

TRANSFER TECHNOLOGY DIRECTOR, ESISAR GRENOBLE INP
Esisar Grenoble INP is an engineering school at the Institut National Polytechnique de Grenoble, specialized in developing embedded systems and digital technology for aerospace applications.

Peru: Exploration Gains Momentum

Peru Mining 2018 Pre-Release
Juniors are back to life and the Andean country offers enormous potential for them.

Advancing Uranium Exploration in Saskatchewan: Preparing for an Upturn

Saskatchewan & Manitoba Mining 2018
While producers must scale down production of uranium in line with the commodity’s demand profile, juniors are aware that they must be more active now to be ready to service demand when it picks up.

Brian Booth

PRESIDENT AND CEO, PEMBROOK COPPER CORP.
Peru Mining 2018 Pre-Release
Pembrook Copper speaks with GBR about the development of its Pecoy deposit in Peru.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS